ABOUT THE HERALD

CONTACT THE HERALD LOCAL AGENCIES DAILY EMAIL UPDATE

Search

CONTRA COSTA HERALD NEWS OF BY AND FOR THE PEOPLE OF CONTRA COSTA COUNTY, CALIFORNIA

ARTS & ENTERTAINMENT BUSINESS COMMUNITY CRIME DINING EDUCATION FAITH HEALTH NEWS POLITICS & ELECTIONS REAL ESTATE



91 research studies affirm naturally acquired immunity to COVID-19: Documented, linked, and quoted

SER 27, 2021 BY PUBLISHER - 2 COMMENTS

BY PAUL ELIAS ALEXANDER

This article was first published by Brownstone Institute. Republished with permission

We should not force COVID vaccines on anyone when the evidence shows that naturally acquired immunity is equal to or more robust and superior to existing vaccines. Instead, we should respect the right of the bodily integrity of individuals to decide for themselves

Public health officials and the medical establishment with the help of the politicized media are misleading the public with assertions that the COVID-19 shots provide greater protection than natural immunity. CDC Director Rochelle Walensky, for example, was deceptive in her October 2020 published LANCET statement that "there is no evidence for lasting protective immunity to SARS-CoV-2 following natural infection" and that "the consequence of waning immunity would present a risk to vulnerable populations for the indefinite future.

Immunology and virology 101 have taught us over a century that natural immunity confers protection against a respiratory virus's outer coat proteins, and not just one, e.g. the SARS-CoV-2 spike glycoprotein. There is even strong evidence for the persistence of antibodi Even the CDC recognizes natural immunity for chicken-pox and measles, mumps, and rubella, but not for COVID-19.

The vaccinated are showing viral loads (very high) similar to the unvaccinated (Acharya et al. and Riemersma et al.), and the vaccinated are as infectious. Riemersma et al. also report Wisconsin data that corroborate how the vaccinated individuals who get infected with the Delta variant can potentially (and are) transmit(ting) SARS-CoV-2 to others (potentially to the vaccinated and unvaccinated).

This troubling situation of the vaccinated being infectious and transmitting the virus emerged in seminal nosocomial outbreak papers by Chau et al. (HCWs in Vietnam), the Finland hospital outbreak (spread among HCWs and patients), and the Israel hospital outbreak (spread among HCWs and patients). These studies also revealed that the PPE and masks were essentially ineffective in the healthcare setting. Again, the Marek's disease in chickens and the vaccination situation explains what we are potentially facing with these leaky vaccines (increased transmission, faster transmission, and more 'hotter' variants).

Moreover, existing immunity should be assessed before any vaccination, via an accurate dependable, and reliable antibody test (or T cell immunity test) or be based on documentation of prior infection (a previous positive PCR or antigen test). Such would be evidence of immunity that is equal to that of vaccination and the immunity should be provided the same societal status as any vaccine-induced immunity. This will function to mitigate the societal anxiety with these forced vaccine mandates and societal upheaval due to job loss, denial of societal privileges etc. Tearing apart the vaccinated and the unvaccinated in a society, separating them is not medically or scientifically supportable

The Brownstone Institute previously documented 30 studies on natural immunity as it relates to Covid-19.

This follow-up chart is the most updated and comprehensive library list of 91 of the highestquality, complete, most robust scientific studies and evidence reports/position statements on natural immunity as compared to the COVID-19 vaccine-induced immunity and allow you to draw your own conclusion.

I've benefited from the input of many to put this together, especially my co-authors:

- Harvey Risch, MD, PhD (Yale School of Public Health)
- Howard Tenenbaum, PhD (Faculty of Medicine, University of Toronto)
- Ramin Oskoui, MD (Foxhall Cardiology, Washington)
- Peter McCullough, MD (Truth for Health Foundation (TFH)), Texas
- Parvez Dara, MD (consultant, Medical Hematologist and Oncologist)

Evidence on natural immunity versus COVID-19 vaccine induced immunity as of October 15. 2021

STUDY / REPORT

TITLE, AUTHOR, AND PREDOMINANT FINDING ON NATURAL IMMUNITY YEAR PUBLISHED

"Cumulative incidence of COVID-19 was examined among 52,238 employees in an American healthcare system. The cumulative













benefit from COVID-19 vaccination.."

incidence of SARS-CoV-2 infection remained almost zero among 1) Necessity of COVID-previously infected unvaccinated subjects, previously infected subjects 10 vaccination in who were vaccinated, and previously uninfected subjects who were previously infected vaccinated, compared with a steady increase in cumulative incidence individuals, Shrestha, among previously uninfected subjects who remained unvaccinated. Not one of the 1359 previously infected subjects who remained unvaccinated had a SARS-CoV-2 infection over the duration of the study. Individuals who have had SARS-CoV-2 infection are unlikely to

2) SARS-CoV-2specific T cell immunity in cases of COVID-19 and SARS, and uninfected

"Studied T cell responses against the structural (nucleocapsid (N) protein) and non-structural (NSP7 and NSP13 of ORF1) regions of SARS CoV-2 in individuals convalescing from coronavirus disease 2019 (COVID-19) (n = 36). In all of these individuals, we found CD4 and CD8 T cells that recognized multiple regions of the N protein...showed that patients (n = 23) who recovered from SARS possess long-lasting memory T cells that are reactive to the N protein of SARS-CoV 17 years controls, Le Bert, 2020 after the outbreak of SARS in 2003; these T cells displayed robust cross-reactivity to the N protein of SARS-CoV-2."

3) Comparing SARS-CoV-2 natural immunity to vaccineinduced immunity: reinfections versus breakthrough infections.Gazit. 2021

"A retrospective observational study comparing three groups: (1) SARS-CoV-2-naïve individuals who received a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine, (2) previously infected individuals who have not been vaccinated, and (3) previously infected and single dose vaccinated individuals found para a 13 fold increased risk of breakthrough Delta infections in double vaccinated persons, and a 27 fold increased risk for symptomatic breakthrough infection in the double vaccinated relative to the natural immunity recovered persons...the risk of hospitalization was 8 times higher in the double vaccinated (para)...this analysis demonstrated that natural immunity affords longer lasting and stronger protection against infection, symptomatic disease and hospitalization due to the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccineinduced immunity."

4) Highly functional virus-specific cellular immune response in

asymptomatic SARS-CoV-2 infection, Le Bert. 2021

85) and symptomatic (n = 75) COVID-19 patients after seroconversion... thus, asymptomatic SARS-CoV-2-infected individuals are not characterized by weak antiviral immunity; on the contrary, they mount a highly functional virus-specific cellular immune response. "A total of 2,653 individuals fully vaccinated by two doses of vaccine

during the study period and 4,361 convalescent patients were included

"Studied SARS-CoV-2-specific T cells in a cohort of asymptomatic (n =

Israel, 2021

Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated 5) Large-scale study individuals (median 1581 AU/mL IQR [533.8-5644.6]) after the second of antibody titer decayvaccination, than in convalescent individuals (median 355.3 AU/mL IQR following BNT162b2 [141.2-998.7]; p<0.001). In vaccinated subjects, antibody titers decreased mRNA vaccine or by up to 40% each subsequent month while in convalescents they SARS-CoV-2 infection, decreased by less than 5% per month...this study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group".

infection risk in Austria, Pilz, 2021

Researchers recorded "40 tentative re-infections in 14, 840 COVID-19 survivors of the first wave (0.27%) and 253 581 infections in 8, 885, 640 individuals of the remaining general population (2.85%) translating into an 6) SARS-CoV-2 re- odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13)...relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies." Additionally, hospitalization in only five out of 14,840 (0.03%) people and death in one out of 14,840 (0.01%) (tentative re-infection).

7) mRNA vaccine-


recognize B.1.1.7 and homing properties depending on prior infection status. Neidleman, 2021

induced SARS-CoV-2-Spike-specific T cells from convalescent vaccinees differed strikingly from those of infection-naïve vaccinees, with phenotypic features suggesting superior long-term persistence and ability to home to the differ in longevity and reassurance that vaccine-elicited T cells respond robustly to the B.1.1.7 and B.1.351 variants, confirm that convalescents may not need a second vaccine dose."

8) Good news: Mild COVID-19 induces lasting antibody protection, Bhandari, 2021

"Months after recovering from mild cases of COVID-19, people still have immune cells in their body pumping out antibodies against the virus that causes COVID-19, according to a study from researchers at Washington University School of Medicine in St. Louis. Such cells could persist for a lifetime, churning out antibodies all the while. The findings, published May 24 in the journal Nature, suggest that mild cases of COVID-19 leave those infected with lasting antibody protection and that repeated bouts of illness are likely to be uncommon."







	PREDOMINANT FINDING ON NATURAL IMMUNITY
	persisted for at least 5 months after infection. Although continued tmonitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared."
10) Evolution of Antibody Immunity to SARS-CoV-2, Gaebler, 2020	"Concurrently, neutralizing activity in plasma decreases by five-fold in pseudo-type virus assays. In contrast, the number of RBD-specific memory B cells is unchanged. Memory B cells display clonal turnover after 6.2 months, and the antibodies they express have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral responsewe conclude that the memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence."
CoV-2 infection in	"Assessed the persistence of serum antibodies following WT SARS- CoV-2 infection at 8 and 13 months after diagnosis in 367 individuals found that NAb against the WT virus persisted in 89% and S-IgG in 97% of subjects for at least 13 months after infection."
of SARS-CoV-2 reinfection over time,	"Eleven large cohort studies were identified that estimated the risk of SARS-CoV-2 reinfection over time, including three that enrolled healthcare workers and two that enrolled residents and staff of elderly care homes. Across studies, the total number of PCR-positive or antibody-positive participants at baseline was 615,777, and the maximum duration of follow-up was more than 10 months in three studies. Reinfection was an uncommon event (absolute rate 0%-11%), with no study reporting an increase in the risk of reinfection over time."
to covid is powerful. Policymakers seem	Makary writes 'it's okay to have an incorrect scientific hypothesis. But when new data proves it wrong, you have to adapt. Unfortunately, many elected leaders and public health officials have held on far too long to the hypothesis that natural immunity offers unreliable protection against covid-19 — a contention that is being rapidly debunked by science. More than 15 studies have demonstrated the power of immunity acquired by previously having the virus. A 700,000-person study from Israel two weeks ago found that those who had experienced prior infections were 27 times less likely to get a second symptomatic covid infection than those who were vaccinated. This affirmed a June Cleveland Clinic study of health-care workers (who are often exposed to the virus), in which none who had previously tested positive for the coronavirus got reinfected. The study authors concluded that 'individuals who have had SARS-CoV-2 infection are unlikely to benefit from covid-19 vaccination.' And in May, a Washington University study found that even a mild covid infection resulted in long-lasting immunity.'
14) SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity, Nielsen, 2021	"203 recovered SARS-CoV-2 infected patients in Denmark between April 3 rd and July 9 th 2020, at least 14 days after COVID-19 symptom recovery report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses the viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8" T-cell responses. Overall, the majority of patients had robust adaptive immune responses, regardless of their disease severity."
infection is similar to that of BNT162b2 vaccine protection: A	hospitalization with COVID-19, severe disease, and death due to COVID- 19. vaccination was highly effective with overall estimated efficacy for documented infection of 928% (Cl:[926, 930]); hospitalization 942% (Cl: [936, 947]); severe illness 944% (Cl:[936, 950]); and death 937% (Cl:[925, 947]). Similarly, the overall estimated level of protection from prior
16) Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously infected or vaccinated employees, Kojima, 2021	"Employees were divided into three groups: (1) SARS-CoV-2 naïve and unvaccinated, (2) previous SARS-CoV-2 infection, and (3) vaccinated. Person-days were measured from the date of the employee first test and truncated at the end of the observation period. SARS-CoV-2 infection was defined as two positive SARS-CoV-2 PCR tests in a 30-day period. 4313, 254 and 739 employee records for groups 1, 2, and 3. previous SARS-CoV-2 infection and vaccination for SARS-CoV-2 were associated with decreased risk for infection or re-infection with SARS- CoV-2 in a routinely screened workforce. The was no difference in the infection incidence between vaccinated individuals and individuals with previous infection."

STUDY / REPORT	
TITLE, AUTHOR, AND	PREDOMINANT FINDING ON NATURAL IMMUNITY
YEAR PUBLISHED	
17) Having SARS- CoV-2 once confers	"Israelis who had an infection were more protected against the Delta
much greater	coronavirus variant than those who had an already highly effective
immunity than a	COVID-19 vaccine_the newly released data show people who once had
vaccine-but	a SARS-CoV-2 infection were much less likely than never-infected,
vaccination remains	vaccinated people to get Delta, develop symptoms from it, or become hospitalized with serious COVID-19."
vital, Wadman, 2021	
	"A systematic antigen-specific immune evaluation in 101 COVID-19
	convalescents; SARS-CoV-2-specific IgG antibodies, and also NAb can
18) One-year	persist among over 95% COVID-19 convalescents from 6 months to 12
	months after disease onset. At least 19/71 (26%) of COVID-19
COVID-19	fconvalescents (double positive in ELISA and MCLIA) had detectable circulating IgM antibody against SARS-CoV-2 at 12m post-disease
	jonset. Notably, the percentages of convalescents with positive SARS-
2021	CoV-2-specific T-cell responses (at least one of the SARS-CoV-2
	antigen S1, S2, M and N protein) were 71/76 (93%) and 67/73 (92%) at
	6m and 12m, respectively."
	"Recovered individuals developed SARS-CoV-2-specific
	immunoglobulin (IgG) antibodies, neutralizing plasma, and memory B
19) Functional SARS-	and memory T cells that persisted for at least 3 months. Our data
CoV-2-Specific	further reveal that SARS-CoV-2-specific IgG memory B cells increased
Immune Memory	over time. Additionally, SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral function:
Persists after Mild	memory T cells secreted cytokines and expanded upon antigen re-
COVID-19, Rodda, 2021	encounter, whereas memory B cells expressed receptors capable of
2021	neutralizing virus when expressed as monoclonal antibodies. Therefore,
	mild COVID-19 elicits memory lymphocytes that persist and display
	functional hallmarks of antiviral immunity."
	"Performed multimodal single-cell sequencing on peripheral blood of
	patients with acute COVID-19 and healthy volunteers before and after
	receiving the SARS-CoV-2 BNT162b2 mRNA vaccine to compare the
	immune responses elicited by the virus and by this vaccineboth infection and vaccination induced robust innate and adaptive immune
	responses, our analysis revealed significant qualitative differences
	between the two types of immune challenges. In COVID-19 patients,
20) Discrete Immune	immune responses were characterized by a highly augmented
Response Signature	interferon response which was largely absent in vaccine recipients.
to SARS-CoV-2 mRN/	Increased interferon signaling likely contributed to the observed
Vaccination Versus	dramatic upregulation of cytotoxic genes in the peripheral T cells and innate-like lymphocytes in patients but not in immunized subjects.
Infection, Ivanova,	Analysis of B and T cell receptor repertoires revealed that while the
2021	majority of clonal B and T cells in COVID-19 patients were effector cells,
	in vaccine recipients clonally expanded cells were primarily circulating
	memory cellswe observed the presence of cytotoxic CD4 T cells in
	COVID-19 patients that were largely absent in healthy volunteers
	following immunization. While hyper-activation of inflammatory responses and cytotoxic cells may contribute to immunopathology in
	severe illness, in mild and moderate disease, these features are
	indicative of protective immune responses and resolution of infection."
	"Bone marrow plasma cells (BMPCs) are a persistent and essential
	source of protective antibodies durable serum antibody titres are
	, maintained by long-lived plasma cells—non-replicating, antigen-specific
21) SARS-CoV-2	plasma cells that are detected in the bone marrow long after the
infection induces	clearance of the antigen _ S-binding BMPCs are quiescent, which
long-lived bone	suggests that they are part of a stable compartment. Consistently,
marrow plasma cells	circulating resting memory B cells directed against SARS-CoV-2 S were detected in the convalescent individuals. Overall, our results indicate
in humans, Turner,	that mild infection with SARS-CoV-2 induces robust antigen-specific,
2021	long-lived humoral immune memory in humans_overall, our data
	provide strong evidence that SARS-CoV-2 infection in humans robustly
	establishes the two arms of humoral immune memory: long-lived bone
	marrow plasma cells (BMPCs) and memory B-cells."
22) SARS-CoV-2	
infection rates of	"The SARS-CoV-2 Immunity and Reinfection Evaluation study 30 625
antibody-positive	participants were enrolled into the study_ a previous history of SARS-
compared with antibody-negative	CoV-2 infection was associated with an 84% lower risk of infection, with
health-care workers in	median protective effect observed 7 months following primary infection.
England: a large,	This time period is the minimum probable effect because
multicentre,	seroconversions were not included. This study shows that previous infection with SARS-CoV-2 induces effective immunity to future
prospective cohort	infections in most individuals."
study (SIREN), Jane	
Hall, 2021	

23) Pandemic peak "Enrolled 200 patient-facing HCWs between March 26 and April 8, SARS-CoV-2 infection 2020..represents a 13% infection rate (i.e. 14 of 112 HCWs) within the 1 and seroconversion month of follow-up in those with no evidence of antibodies or viral rates in London shedding at enrolment. By contrast, of 33 HCWs who tested positive by frontline health-care serology but tested negative by RT-PCR at enrolment, 32 remained workers, Houlihan, negative by RT-PCR through follow-up, and one tested positive by RT-

STUDY / REPORT	
TITLE, AUTHOR, AND	PREDOMINANT FINDING ON NATURAL IMMUNITY
YEAR PUBLISHED	
2020	PCR on days 8 and 13 after enrolment."
24) Antibodies to	"Critical to understand whether infection with Severe Acute Respiratory
SARS-CoV-2 are associated with	Syndrome Coronavirus 2 (SARS-CoV-2) protects from subsequent
protection against	reinfection 12219 HCWs participatedprior SARS-CoV-2 infection that
reinfection, Lumley,	generated antibody responses offered protection from reinfection for
2021	most people in the six months following infection."
25) Longitudinal	
analysis shows	"Evaluate 254 COVID-19 patients longitudinally up to 8 months and find
durable and broad	durable broad-based immune responses. SARS-CoV-2 spike binding
immune memory	and neutralizing antibodies exhibit a bi-phasic decay with an extended
after SARS-CoV-2	half-life of >200 days suggesting the generation of longer-lived plasma cells most recovered COVID-19 patients mount broad, durable
persisting antibody	immunity after infection, spike IgG+ memory B cells increase and persist
responses and	post-infection, durable polyfunctional CD4 and CD8 T cells recognize
memory B and	distinct viral epitope regions."
T cells, Cohen, 2021	
26) Single cell profiling	"Used single-cell RNA sequencing and functional assays to compare
of T and B cell	humoral and cellular responses to two doses of mRNA vaccine with
	responses observed in convalescent individuals with asymptomatic
SARS-CoV-2 mRNA vaccine.	disease natural infection induced expansion of larger CD8 T cell clones occupied distinct clusters, likely due to the recognition of a broader set
	of viral epitopes presented by the virus not seen in the mRNA vaccine."
27) SARS-CoV-2	*SARS-CoV-2 antibody-positive persons from April 16 to December 31,
antibody-positivity	SARS-CoV-2 antibody-positive persons from April 16 to December 31, 2020 with a PCR-positive swab ≥14 days after the first-positive antibody
protects against	test were investigated for evidence of reinfection, 43,044 antibody-
reinfection for at least	positive persons who were followed for a median of 16.3 weeks
seven months with	reinfection is rare in the young and international population of Qatar.
95% efficacy, Abu-	Natural infection appears to elicit strong protection against reinfection
Raddad, 2021	with an efficacy ~95% for at least seven months."
28) Orthogonal SARS-	"Conducted a serological study to define correlates of immunity against
CoV-2 Serological Assays Enable	SARS-CoV-2. Compared to those with mild coronavirus disease 2019
Assays Enable Surveillance of Low-	(COVID-19) cases, individuals with severe disease exhibited elevated
Prevalence	virus-neutralizing titers and antibodies against the nucleocapsid (N) and
Communities and	the receptor binding domain (RBD) of the spike protein_neutralizing and spike-specific antibody production persists for at least 5-
Reveal Durable	7 months nucleocapsid antibodies frequently become undetectable by
Humoral Immunity,	5–7 months."
Ripperger, 2020	
	"In the general population using representative data from 7,256 United
29) Anti-spike	Kingdom COVID-19 infection survey participants who had positive swab
	SARS-CoV-2 PCR tests from 26-April-2020 to 14-June-2021we estimated antibody levels associated with protection against reinfection
	likely last 15-2 years on average, with levels associated with protection
	from severe infection present for several years. These estimates could
	inform planning for vaccination booster strategies."
	12,541 health care workers participated and had anti-spike IgG
	measured; 11,364 were followed up after negative antibody results and
30) Antibody Status	1265 after positive results, including 88 in whom seroconversion
and Incidence of	occurred during follow-upa total of 223 anti-spike-seronegative health
	care workers had a positive PCR test (1.09 per 10,000 days at risk), 100
in Health Care Workers, Lumley,	during screening while they were asymptomatic and 123 while symptomatic, whereas 2 anti-spike-seropositive health care workers
2021	symptomatic, whereas 2 anti-spike-seropositive nealth care workers had a positive PCR test., the presence of anti-spike or anti-nucleocapsid
	IgG antibodies was associated with a substantially reduced risk of
	SARS-CoV-2 reinfection in the ensuing 6 months."
	"A study of the blood of older people who survived the 1918 influenza
	pandemic reveals that antibodies to the strain have lasted a lifetime and
	can perhaps be engineered to protect future generations against similar
	strainsthe group collected blood samples from 32 pandemic survivors
	aged 91 to 101.the people recruited for the study were 2 to 12 years old
	in 1918 and many recalled sick family members in their households,
Data Deservative Contin	which suggests they were directly exposed to the virus, the authors
31) Researchers find long-lived immunity	report. The group found that 100% of the subjects had serum- neutralizing activity against the 1918 virus and 94% showed serologic
to 1918 pandemic	reactivity to the 1918 hemagglutinin. The investigators generated B
virus, CIDRAP, 2008	lymphoblastic cell lines from the peripheral blood mononuclear cells of
and the actual 2008	eight subjects. Transformed cells from the blood of 7 of the 8 donors
NATURE journal	yielded secreting antibodies that bound the 1918 hemagglutinin." Yu:
publication by Yu	"here we show that of the 32 individuals tested that were born in or
	before 1915, each showed sero-reactivity with the 1918 virus, nearly 90
	years after the pandemic. Seven of the eight donor samples tested had
	circulating B cells that secreted antibodies that bound the 1918 HA. We

from three separate donors. These antibodies also cross-reacted with the genetically similar HA of a 1930 swine H1N1 influenza strain."

"No significant difference was observed between the 20B and 19A

isolated B cells from subjects and generated five monoclonal antibodies that showed potent neutralizing activity against 1918 virus

isolates for HCWs with mild COVID-19 and critical patients. However, a 32) Live virus significant decrease in neutralisation ability was found for 201/501Y.V1 in neutralisation testing comparison with 19A isolate for critical patients and HCWs 6-months patients and subjects post infection. Concerning 20H/501Y.V2, all populations had a significant reduction in neutralising antibody titres in comparison with vaccinated against the 19A isolate. Interestingly, a significant difference in neutralisation 19A. 20B. 20I/501Y.V1 capacity was observed for vaccinated HCWs between the two variants and 20H/501Y.V2 whereas it was not significant for the convalescent groups...the reduced isolates of SARS-CoV neutralising response observed towards the 20H/501Y.V2 in 2. Gonzalez, 2021 comparison with the 19A and 201/501Y.V1 isolates in fully immunized subjects with the BNT162b2 vaccine is a striking finding of the study."

33) Differential effects

of the second SARS- "Characterized SARS-CoV-2 spike-specific humoral and cellular CoV-2 mRNA vaccine immunity in naïve and previously infected individuals during full BNT162b2 vaccination...results demonstrate that the second dose dose on T cell immunity in naïve and increases both the humoral and cellular immunity in naïve individuals COVID-19 recovered On the contrary, the second BNT162b2 vaccine dose results in a individuals, Camara, reduction of cellular immunity in COVID-19 recovered individuals. 2021

34) Op-Ed: Quit Ignoring Natural COVID Immunity. Klausner, 2021

"Epidemiologists estimate over 160 million people worldwide have recovered from COVID-19. Those who have recovered have an astonishingly low frequency of repeat infection, disease, or death."

"To evaluate evidence of SARS-CoV-2 infection based on diagnostic nucleic acid amplification test (NAAT) among patients with positive vs

cohort study of clinical laboratory and linked claims data, the cohort

with positive antibody test results were initially more likely to have

suggesting that seropositivity is associated with protection from

"Investigated the risk of subsequent SARS-CoV-2 infection among young adults (CHARM marine study) seropositive for a previous infection...enrolled 3249 participants, of whom 3168 (98%) continued into

seropositive participants, 19 (10%) had at least one positive PCR test for

SARS-CoV-2 during the 6-week follow-up (1·1 cases per person-year).

In contrast, 1079 (48%) of 2247 seronegative participants tested positive

(6-2 cases per person-year). The incidence rate ratio was 0-18 (95% Cl

positive NAAT results, consistent with prolonged RNA shedding, but became markedly less likely to have positive NAAT results over time,

35) Association of negative test results for antibodies in an observational descriptive SARS-CoV-2 opositive Antibody included 3 257 478 unique patients with an index antibody test...patients Test With Risk of

Future Infection,

Harvey, 2021

infection."

36) SARS-CoV-2 the 2-week quarantine period. 3076 (95%) participants...Among 189 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study, Letizia, 011-028: p<0.001).infected seropositive participants had viral loads that

were about 10-times lower than those of infected seronegative participants (ORF1ab gene cycle threshold difference 3:95 [95% Cl 1:23-6.67]; p=0.004). 37) Associations of "Of 9.180 individuals with no record of vaccination but with a record of Vaccination and of prior infection at least 90 days before the PCR test (group 3), 7694 could

Prior Infection With be matched to individuals with no record of vaccination or prior Positive PCR Test infection (group 2), among whom PCR positivity was 1.01% (95% Cl, Results for SARS- 0.80%-1.26%) and 3.81% (95% Cl, 3.39%-4.26%), respectively. The relative risk for PCR positivity was 0.22 (95% Cl, 0.17-0.28) for vaccinated CoV-2 in Airline Passengers Arriving in individuals and 0.26 (95% CI, 0.21-0.34) for individuals with prior infection Qatar, Bertollini, 2021 compared with no record of vaccination or prior infection.

"Followed up with a subsample of our previous sero-survey participants to assess whether natural immunity against SARS-CoV-2 38) Natural immunity was associated with a reduced risk of re-infection (India)... out of the 2238 against COVID-19 participants, 1170 were sero-positive and 1068 were sero-negative for significantly reduces antibody against COVID-19. Our survey found that only 3 individuals in the risk of reinfection: the sero-positive group got infected with COVID-19 whereas 127 findings from a cohort individuals reported contracting the infection the sero-negative group. from the 3 sero-positives re-infected with COVID-19, one had participants, Mishra, hospitalization, but did not require oxygen support or critical care. development of antibody following natural infection not only protects against re-infection by the virus to a great extent, but also safeguards against progression to severe COVID-19 disease."

39) Lasting immunity found after recovery from COVID-19, NIH, 2021

of sero-survey

2021

"The researchers found durable immune responses in the majority of people studied. Antibodies against the spike protein of SARS-CoV-2, which the virus uses to get inside cells, were found in 98% of participants one month after symptom onset. As seen in previous studies, the number of antibodies ranged widely between individuals. But promisingly, their levels remained fairly stable over time, declining only modestly at 6 to 8 months after infection... virus-specific B cells increased over time. People had more memory B cells six months after symptom onset than at one month afterwards... levels of T cells for the virus also remained high after infection. Six months after sympton onset, 92% of participants had CD4+ T cells that recognized the virus. 95% of the people had at least 3 out of 5 immune-system components that could recognize SARS-CoV-2 up to 8 months after infection."

YEAR PUBLISHED

40) SARS-CoV-2 "The seropositive rate in the convalescent individuals was above 95% at Natural Antibody all sampling time points for both assays and remained stable over time Response Persists for that is, almost all convalescent individuals developed antibodies. at Least 12 Months in results show that SARS-CoV-2 antibodies persisted at least 12 months Nationwide Study after symptom onset and maybe even longer, indicating that COVID-19convalescent individuals may be protected from reinfection." Islands, Petersen, 2021

41) SARS-CoV-2specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells, Jung, 2021

"ex vivo assays to evaluate SARS-CoV-2-specific CD4⁺ and CD8⁺ T cell responses in COVID-19 convalescent patients up to 317 days postsymptom onset (DPSO), and find that memory T cell responses are maintained during the study period regardless of the severity of COVID-19. In particular, we observe sustained polyfunctionality and proliferation capacity of SARS-CoV-2-specific T cells. Among SARS-CoV-2-specific CD4* and CD8* T cells detected by activation-induced markers, the proportion of stem cell-like memory T (T_{SCM}) cells is increased, peaking at approximately 120 DPSO."

"Analyzed 42 unexposed healthy donors and 28 mild COVID-19 subjects up to 5 months from the recovery for SARS-CoV-2 specific 42) Immune Memory immunological memory. Using HLA class II predicted peptide megapools, we identified SARS-CoV-2 cross-reactive CD4⁺ T cells in in Mild COVID-19 Patients and around 66% of the unexposed individuals. Moreover, we found Unexposed Donors detectable immune memory in mild COVID-19 patients several months Reveals Persistent T after recovery in the crucial arms of protective adaptive immunity; Cell Responses After CD4* T cells and B cells, with a minimal contribution from CD8* T cells SARS-CoV-2 Infection, Interestingly, the persistent immune memory in COVID-19 patients is Ansari, 2021 predominantly targeted towards the Spike glycoprotein of the SARS-CoV-2. This study provides the evidence of both high magnitude preexisting and persistent immune memory in Indian population. "Current evidence points to most individuals developing strong protective immune responses following natural infection with SARSCoV-2. Within 4 weeks following infection, 90-99% of individuals infected with the SARS-CoV-2 virus develop detectable neutralizing antibodies. The strength and duration of the immune responses to 43) COVID-19 natural SARS-CoV-2 are not completely understood and currently available immunity, WHO, 2021 data suggests that it varies by age and the severity of symptoms. Available scientific data suggests that in most people immun responses remain robust and protective against reinfection for at least 6-8 months after infection (the longest follow up with strong scientific evidence is currently approximately 8 months)." "We conclude that memory antibodies selected over time by natural 44) Antibody infection have greater potency and breadth than antibodies elicited by Evolution after SARS- vaccination...boosting vaccinated individuals with currently available CoV-2 mRNA mRNA vaccines would produce a quantitative increase in plasma Vaccination, Cho, 2021 neutralizing activity but not the qualitative advantage against variants obtained by vaccinating convalescent individuals." "Measured antibodies in serum samples from 30,576 persons in 45) Humoral Immune Iceland...of the 1797 persons who had recovered from SARS-CoV-2 Response to SARS-infection, 1107 of the 1215 who were tested (g11%) were seropositive. results indicate risk of death from infection was 0.3% and that antiviral Iceland, Gudbiartsson , antibodies against SARS-CoV-2 did not decline within 4 months after diagnosis (para)." 46) Immunological "Analyzed multiple compartments of circulating immune memory to memory to SARS- SARS-CoV-2 in 254 samples from 188 COVID-19 cases, including 43 CoV-2 assessed for samples at ≥ 6 months post-infection...IgG to the Spike protein was up to 8 months after relatively stable over 6+ months. Spike-specific memory B cells were infection, Dan, 2021 more abundant at 6 months than at 1 month post symptom onset."

47) The prevalence of

adaptive immunity to "Fifty-four studies, from 18 countries, with a total of 12 011 447 COVID-19 and individuals, followed up to 8 months after recovery, were included. At reinfection after 6-8 months after recovery, the prevalence of detectable SARS-CoV-2 recovery - a specific immunological memory remained high; IgG – 90.4%... pooled systematic review and Individuals who recovered from COVID-19 had an 81% reduction in odds meta-analysis of 12 of a reinfection (OR 0.19, 95% Cl 0.1 – 0.3, I² = 90.5%, 5 studies)." 011 447 individuals, Chivese, 2021

a Retrospective Cohort Study, Sheehan, 2021

48) Reinfection Rates *Retrospective cohort study of one multi-hospital health system among Patients who included 150.325 patients tested for COVID-19 infection_prior infection in patients with COVID-19 was highly protective against reinfection and Positive for COVID-19. symptomatic disease. This protection increased over time, suggesting that viral shedding or ongoing immune response may persist beyond 90 days and may not represent true reinfection."

49) Assessment of

SARS-CoV-2 "The study results suggest that reinfections are rare events and patients Reinfection 1 Year who have recovered from COVID-19 have a lower risk of reinfection After Primary Infection Natural immunity to SARS-CoV-2 appears to confer a protective effect

YEAR PUBLISHED

in a Population in for at least a year, which is similar to the protection reported in recent Lombardy, Italy, vaccine studies."

Vitale, 2020

with protection

in longevity and

Neidleman, 2021

50) Prior SARS-CoV-2 . "We observed no symptomatic reinfections in a cohort of healthcare infection is associated workers.this apparent immunity to re-infection was maintained for at least 6 months...test positivity rates were 0% (0/128 [95% CI: 0-2.9]) in against symptomatic those with previous infection compared to 13.7% (290/2115 [95% Cl: 12.3reinfection, Hanrath, 1521) in those without (P<0.0001 χ^2 test)."

51) mRNA vaccine-

respond identically to and altered the phenotypic properties of SARS-CoV-2-specific T cells, SARS-CoV-2 variants while in convalescents the second dose changed neither. Spike-specific of concern but differ T cells from convalescent vaccinees differed strikingly from those of infection-naïve vaccinees, with phenotypic features suggesting superior homing properties long-term persistence and ability to home to the respiratory tract depending on prior including the nasopharynx.*

"Using HLA class I and II predicted peptide "megapools," circulating

52) Targets of T Cell SARS-CoV-2-specific CD8' and CD4' T cells were identified in -70% and CoV-2 Coronavirus in Humans with COVID-19 Disease and

2020

100% of COVID-19 convalescent patients, respectively. CD4* T cell responses to spike, the main target of most vaccine efforts, were robust and correlated with the magnitude of the anti-SARS-CoV-2 IgG and IgA titers. The M, spike, and N proteins each accounted for 11%–27% of the total CD4* response, with additional responses commonly targeting nsp3, nsp4, ORE3a, and ORE8, among others. For CD8⁺ T cells, spike and M were recognized, with at least eight SARS-CoV-2 ORFs targeted.

53) NIH Director's 2021

"Much of the study on the immune response to SARS-CoV-2, the novel coronavirus that causes COVID-19, has focused on the production of antibodies. But, in fact, immune cells known as memory T cells also Blog: Immune T Cells play an important role in the ability of our immune systems to protect May Offer Lasting us against many viral infections, including—it now appears—COVID-Protection Against 19.An intriguing new study of these memory T cells suggests they might COVID-19, Collins, protect some people newly infected with SARS-CoV-2 by remembering past encounters with other human coronaviruses. This might potentially explain why some people seem to fend off the virus and may be less susceptible to becoming severely ill with COVID-19."

54) Ultrapotent

2021

antibodies against "Our study demonstrates that convalescent subjects previously diverse and highly infected with ancestral variant SARS-CoV-2 produce antibodies that transmissible SARS- cross-neutralize emerging VOCs with high potency...potent against 23 CoV-2 variants, Wang, variants, including variants of concern."

55) Why COVID-19 Be Required for All Americans, Makary, 2021

"Requiring the vaccine in people who are already immune with natural immunity has no scientific support. While vaccinating those people may be beneficial - and it's a reasonable hypothesis that vaccination may Vaccines Should Not bolster the longevity of their immunity – to argue dogmatically that they must get vaccinated has zero clinical outcome data to back it. As a matter of fact, we have data to the contrary: A Cleveland Clinic study found that vaccinating people with natural immunity did not add to their level of protection."

56) Protracted yet coordinated

"Screened 21 well-characterized, longitudinally-sampled convalescent convalescence, Ma, memory." 2021

differentiation of long- donors that recovered from mild COVID-19...following a typical case of lived SARS-CoV-2- mild COVID-19, SARS-CoV-2-specific CD8+ T cells not only persist but specific CD8+ T cells continuously differentiate in a coordinated fashion well into during COVID-19 convalescence, into a state characteristic of long-lived, self-renewing

Measles Virus-

2004

57) Decrease in antigen-specific T cells over time since vaccination. In a cross-sectional study of healthy subjects with a history of MV vaccination, we found Specific CD4 T Cell that MV-specific CD4 and CD8 T cells could be detected up to 34 years Memory in Vaccinatedafter vaccination. The levels of MV-specific CD8 T cells and MV-specific Subjects, Naniche. IgG remained stable, whereas the level of MV-specific CD4 T cells decreased significantly in subjects who had been vaccinated >21 years earlier."

"Characterized the profiles of measles vaccine (MV) vaccine-induced

2019

"The success of vaccines is dependent on the generation and maintenance of immunological memory. The immune system can remember previously encountered pathogens, and memory B and T 58) Remembrance of cells are critical in secondary responses to infection. Studies in mice Things Past: Long- have helped to understand how different memory B cell populations Term B Cell Memory are generated following antigen exposure and how affinity for the After Infection and antigen is determinant to B cell fate... upon re-exposure to an antigen the Vaccination, Palm, memory recall response will be faster, stronger, and more specific than a naïve response. Protective memory depends first on circulating antibodies secreted by LLPCs. When these are not sufficient for

STUDY / REPORT
TITLE, AUTHOR, AND PREDOMINANT FINDING ON NATURAL IMMUNITY
YEAR PUBLISHED

	immediate pathogen neutralization and elimination, memory B cells are recalled."
59) SARS-CoV-2 specific memory B- cells from individuals with diverse disease severities recognize SARS-CoV-2 variants of concern, Lyski, 202	"Examined the magnitude, breadth, and durability of SARS-CoV-2 specific antibodies in two distinct B-cell compartments: long-lived plasma cell-derived antibodies in the plasma, and peripheral memory B-cells along with their associated antibody profiles elicited after <i>in</i> <i>vitro</i> stimulation. We found that magnitude varied amongst individuals, but was the highest in hospitalized subjects. Variants of concern (VoC) - RBD-reactive antibodies were found in the plasma of 72% of samples in this investigation, and VoC-RBD-reactive memory B-cells were found in all but 1 subject at a single time-point. This finding, that VoC-RBD- reactive MBCs are present in the peripheral blood of all subjects including those that experienced asymptomatic or mild disease,
	provides a reason for optimism regarding the capacity of vaccination, prior infection, and/or both, to limit disease severity and transmission of variants of concern as they continue to arise and circulate.*
60) Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection, Wang, 2021	"T-cell immunity is important for recovery from COVID-19 and provides heightened immunity for re-infection. However, little is known about the SARS-CoV-2-specific T-cell immunity in virus-exposed individuals report virus-specific CD4 ⁺ and CD8 ⁺ T-cell memory in recovered COVID-19 patients and close contactsclose contacts are able to gain T-cell immunity against SARS-CoV-2 despite lacking a detectable infection."
61) CD8+ T-Cell Responses in COVID- 19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS- CoV-2 Circulating Variants, Redd, 2021and Lee, 2021	"The CD4 and CD8 responses generated after natural infection are equally robust, showing activity against multiple "epitopes" (little segments) of the spike protein of the virus. For instance, CD8 cells responds to 52 epitopes and CD4 cells respond to 57 epitopes across the spike protein, so that a few mutations in the variants cannot knock out such a robust and in-breadth T cell response.only 1 mutation found in Beta variant-spike overlapped with a previously identified epitope (1/52), suggesting that virtually all anti-SARS-CoV-2 CD8* T-cell responses should recognize these newly described variants."
62) Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2,La Jolla, Crotty and Sette, 2020	
63) Selective and cross-reactive SARS-	*Found that the pre-existing reactivity against SARS-CoV-2 comes from memory T cells and that cross-reactive T cells can specifically recognize a SARS-CoV-2 epitope as well as the homologous epitope from a common cold coronavirus. These findings underline the importance of determining the impacts of pre-existing immune memory in COVID-19 disease severity."
64) Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection, Dehgani- Mobaraki, 2021	"Better understanding of antibody responses against SARS-CoV-2 after natural infection might provide valuable insights into the future implementation of vaccination policies. Longitudinal analysis of IgG antibody titers was carried out in 32 recovered COVID-19 patients based in the Umbria region of Italy for 14 months after Mild and Moderately-Severe infection.study findings are consistent with recent studies reporting antibody persistency suggesting that induced SARS- CoV-2 immunity through natural infection, might be very efficacious against re-infection (>90%) and could persist for more than six months. Our study followed up patients up to 14 months demonstrating the presence of anti-S-RBD IgG in 96.8% of recovered COVID-19 subjects."
65) Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19, Juno, 2020	*Characterized humoral and circulating follicular helper T cell (cTFH) immunity against spike in recovered patients with coronavirus disease 2019 (COVID-19). We found that S-specific antibodies, memory B cells and cTFH are consistently elicited after SARS-CoV-2 infection, demarking robust humoral immunity and positively associated with plasma neutralizing activity.*
SARS-CoV-2 in convalescent individuals, Robbiani, 2020 67) Rapid generation	"149 COVID-19-convalescent individualsantibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed cosely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC ₅₀ values) as low as 2 ng ml ^{-1,*}
of durable B cell memory to SARS- CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence,	"COVID-19 patients rapidly generate B cell memory to both the spike and nucleocapsid antigens following SARS-CoV-2 infection_RBD- and NCP-specific IgG and Bmem cells were detected in all 25 patients with a history of COVID-19."

STUDY / REPORT	
	PREDOMINANT FINDING ON NATURAL IMMUNITY
YEAR PUBLISHED	
68) Had COVID? You'll probably make antibodies for a lifetime, Callaway, 2021	¹ People who recover from mild COVID-19 have bone-marrow cells that can churn out antibodies for decadesthe study provides evidence that immunity triggered by SARS-CoV-2 infection will be extraordinarily long-lasting. [*]
show preexisting antibody reactivity	In greater Vancouver Canada, "using a highly sensitive multiplex assay and positive/negative thresholds established in infants in whom maternal antibodies have waned, we determined that more than 90% of uninfected adults showed antibody reactivity against the spike protein, receptor-binding domain (RBD), N-terminal domain (NTD), or the nucleocapsid (N) protein from SARS-CoV-2."
	"The results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses."
breadth against	*A cohort of 63 individuals who have recovered from COVID-19 assessed at 1.3. 6.2 and 12 months after SARS-CoV-2 infection.the data suggest that immunity in convalescent individuals will be very long lasting.*
72) One Year after Milc COVID-19: The Majority of Patients	I
Four Still Suffer from Long-Term Symptoms, Rank,	"Long-lasting immunological memory against SARS-CoV-2 after mild COVID-19."
2021	
73) <mark>IDSA</mark> , 2021	"Immune responses to SARS-CoV-2 following natural infection can persist for at least 11 months_ natural infection (as determined by a prior positive antibody or PCR-test result) can confer protection against SARS-CoV-2 infection."
reinfection with SARS- CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population- level observational	Denmark, "during the first surge (ie, before June, 2020), 533 381 people were tested, of whom 11 727 (2:20%) were PCR positive, and 525 339 were eligible for follow-up in the second surge, of whom 11 068 (2:11%) had tested positive during the first surge. Among eligible PCR-positive individuals from the first surge of the epidemic, 72 (0:65% [95% CI 0:51- 0:82]) tested positive again during the second surge compared with 16 819 (3:27% [3:22-3:32]) of 514 271 who tested negative during the first surge (adjusted RR 0:195 [95% CI 0:155-0:246])."
75) Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity, Moderbacher, 2020	*Adaptive immune responses limit COVID-19 disease severity_multiple coordinated arms of adaptive immunity control better than partial responses_completed a combined examination of all three branches of adaptive immunity at the level of SARS-CoV-2-specific CD4' and CD8' T cell and neutralizing antibody responses in acute and convalescent subjects. SARS-CoV-2-specific CD4' and CD8' T cells were each associated with milder disease. Coordinated SARS-CoV-2- specific adaptive immune responses were associated with milder disease, suggesting roles for both CD4' and CD8' T cells in protective immunity in COVID-19.*
SARS-CoV-2-Specific Humoral and Cellular mmunity in COVID-19 Convalescent Individuals, Ni, 2020	"Collected blood from COVID-19 patients who have recently become virus-free, and therefore were discharged, and detected SARS-CoV-2- specific humoral and cellular immunity in eight newly discharged patients. Follow-up analysis on another cohort of six patients 2 weeks post discharge also revealed high titers of immunoglobulin G (IgG) antibodies. In all 14 patients tested. 13 displayed serum-neutralizing activities in a pseudotype entry assay. Notably, there was a strong correlation between neutralization antibody titers and the numbers of virus-specific T cells."
CoV-2-specific T-cell mmunity is maintained at 6 months following	*Analysed the magnitude and phenotype of the SARS-CoV-2 cellular immune response in 100 donors at six months following primary infection and related this to the profile of antibody level against spike. nucleoprotein and RBD over the previous six months. T-cell immune responses to SARS-CoV-2 were present by ELISPOT and/or ICS analysis in all donors and are characterised by predominant CD4+ T cell .responses with strong IL-2 cytokine expression functional SARS-CoV- 2-specific T-cell responses are retained at six months following infection.*

"Performed a comprehensive analysis of SARS-CoV-2-specific CD4+

and CD8+ T cell responses from COVID-19 convalescent subjects 78) Negligible impact recognizing the ancestral strain, compared to variant lineages B.1.1.7. of SARS-CoV-2 B.1.351, P.1, and CAL 20C as well as recipients of the Moderna (mRNAvariants on CD4⁺ and 1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines... the CD8⁺ T cell reactivity sequences of the vast majority of SARS-CoV-2 T cell epitopes are not in COVID-19 exposed affected by the mutations found in the variants analyzed. Overall, the donors and results demonstrate that CD4+ and CD8+ T cell responses in vaccinees, Tarke, 2021 convalescent COVID-19 subjects or COVID-19 mRNA vaccinees are not

substantially affected by mutations."

79) A 1 to 1000 SARS-CoV-2 reinfection

proportion in Israel. "out of 149,735 individuals with a documented positive PCR test members of a large between March 2020 and January 2021, 154 had two positive PCR tests healthcare provider in at least 100 days apart, reflecting a reinfection proportion of 1 per 1000.

Israel: a preliminary report. Perez. 2021

"Measured plasma and/or serum antibody responses to the receptorbinding domain (RBD) of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with SARS-CoV-2 (of which 93% 80) Persistence and required hospitalization) up to 122 days after symptom onset and decay of human compared them to responses in 1548 individuals whose blood samples antibody responses to were obtained prior to the pandemic...IgG antibodies persisted at the receptor binding detectable levels in patients beyond 90 days after symptom onset, and domain of SARS-CoV seroreversion was only observed in a small percentage of individuals. 2 spike protein in The concentration of these anti-RBD IgG antibodies was also highly COVID-19 patients, correlated with pseudovirus NAb titers, which also demonstrated minimal decay. The observation that IgG and neutralizing antibody responses persist is encouraging, and suggests the development of

81) A population-CoV-2 antibody 2021

lyer, 2020

national clinical laboratory registry of patients tested by nucleic acid based analysis of the amplification (NAAT) and serologic assays... specimens from 39,086 longevity of SARS- individuals with confirmed positive COVID-19...both S and N SARS-CoV-2 antibody results offer an encouraging view of how long humans may seropositivity in the have protective antibodies against COVID-19, with curve smoothing United States, Alfego, showing population seropositivity reaching 90% within three weeks regardless of whether the assay detects N or S-antibodies. Most importantly, this level of seropositivity was sustained with little decay through ten months after initial positive PCR."

robust systemic immune memory in individuals with severe infection. "To track population-based SARS-CoV-2 antibody seropositivity duration across the United States using observational data from a

82) What are the roles *Progress in laboratory markers for SARS-CoV2 has been made with protective immunity against SARS-CoV-2? Hellerstein, 2020

identification of epitopes on CD4 and CD8 T-cells in convalescent blood. durable, high- quality These are much less dominated by spike protein than in previous coronavirus infections. Although most vaccine candidates are focusing on spike protein as antigen, natural infection by SARS-CoV-2 induces broad epitope coverage, cross-reactive with other betacoronviruses."

83) Broad and strong memory CD4⁺ and CD8⁺ T cells induced by SARS-CoV-2 in UK convalescent COVID-

2020

memory T cell responses from COVID-19 were significantly higher in severe compared to mild COVID-19 cases, and this effect was most marked in response to spike, membrane, and ORF3a proteins..total and spike-specific T cell responses correlated with the anti-Spike, anti-Receptor Binding Domain (RBD) as well as anti-Nucleoprotein (NP) endpoint antibody titre_furthermore showed a higher ratio of SARS-19 patients, Peng, CoV-2-specific

"Study of 42 patients following recovery from COVID-19, including 28 mild and 14 severe cases, comparing their T cell responses to those of 16 control donors...found the breadth, magnitude and frequency of

CD8* to CD4* T cell responses..immunodominant epitope clusters and peptides containing T cell epitopes identified in this study will provide critical tools to study the role of virus-specific T cells in control and resolution of SARS-CoV-2 infections.

"SARS-CoV-2-specific memory T cells will likely prove critical for long-84) Robust T Cell term immune protection against COVID-19...mapped the functional and Immunity in phenotypic landscape of SARS-CoV-2-specific T cell responses in Convalescent unexposed individuals, exposed family members, and individuals with acute or convalescent COVID-19_collective dataset shows that SARS-CoV-2 elicits broadly directed and functionally replete memory T cell COVID-19, Sekine, responses, suggesting that natural exposure or infection may prevent 2020 recurrent episodes of severe COVID-19."

85) Potent SARS-CoV-

2-Specific T Cell

Immunity and Low "Provide a full picture of cellular and humoral immune responses of Anaphylatoxin Levels COVID-19 patients and prove that robust polyfunctional CD8* T cell Correlate With Mild responses concomitant with low anaphylatoxin levels correlate with Disease Progression inmild infections."

COVID-19 Patients, Lafron, 2021

YEAR PUBLISHED	
86) SARS-CoV-2 T- cell epitopes define heterologous and COVID-19 induced T- cell recognition, Nelde, 2020	cross-reactive HLA class I and HLA-DR T-cell epitopes in SARS-CoV-2 convalescents (n - 180) as well as unexposed individuals (n - 185) and confirming their relevance for immunity and COVID-19 disease course. cross-reactive SARS-CoV-2 T-cell epitopes revealed pre-existing T-cell responses in 81% of unexposed individuals, and validation of similarity to common cold human coronaviruses provided a functional basis for postulated heterologous immunity in SARS-CoV-2 infectionintensity of T-cell responses and recognition rate of T-cell epitopes was significantly higher in the convalescent donors compared to unexposed individuals, suggesting that not only expansion, but also diversity spread of SARS-CoV-2 T-cell responses occur upon active infection.*
87) Karl Friston: up to 80% not even susceptible to Covid- 19, Sayers, 2020	"Results have just been published of a study suggesting that 40%-60% of people who have not been exposed to coronavirus have resistance at the T-cell level from other similar coronaviruses like the common coldthe true portion of people who are not even susceptible to Covid-1g may be as high as 80%."
88) CD8' T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses, Lineburg, 2021	"Screening of SARS-CoV-2 peptide pools revealed that the nucleocapsid (N) protein induced an immunodominant response in HLA-B7" COVID-19-recovered individuals that was also detectable in unexposed donors. the basis of selective T cell cross-reactivity for an immunodominant SARS-CoV-2 epitope and its homologs from seasonal coronaviruses, suggesting long-lasting protective immunity."
recognition reveals strong immunodominance	L°COVID-19 patients showed strong T cell responses, with up to 25% of all CD8° lymphocytes specific to SARS-CoV-2-derived immunodominant epitopes, derived from ORF1 (open reading frame 1), ORF3, and Nucleocapsid (N) protein. A strong signature of T cell activation was observed in COVID-19 patients, while no T cell activation was seen in the 'non-exposed' and 'high exposure risk' healthy donors."
90) Equivalency of Protection from Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: / Systematic Review and Pooled Analysis, Shenai, 2021	"Systematic review and pooled analysis of clinical studies to date, that (1) specifically compare the protection of natural immunity in the COVID- recovered versus the efficacy of full vaccination in the COVID-naive, and (2) the added benefit of vaccination in the COVID-recovered, for prevention of subsequent SARS-CoV-2 infection_review demonstrates that natural immunity in COVID-recovered individuals is, at least, equivalent to the protection afforded by full vaccination of COVID-naive populations. There is a modest and incremental relative benefit to vaccination in COVID-recovered individuals; however, the net benefit is marginal on an absolute basis."
91) ChAdOx1nCoV-19 effectiveness during an unprecedented	"The third key finding is that previous infections with SARS-CoV-2 were significantly protective against all studied outcomes, with an effectiveness of 93% (87 to 96%) seen against symptomatic infections,

effe an unprecedented 2021

of 93% (87 to 96%) se n against symp an unprecedented surge in SARS CoV-2 infections, Satwik, 2021 surge in SARS coV-2 infections, Satwik, single or double dose vaccine."

AUTHOR

Paul Elias Alexander

Dr. Alexander holds a PhD. He has experience in epidemiology and in the teaching of clinical epidemiology, evidence-based medicine, and research methodology. Dr Alexander is a former Assistant Professor at McMaster University in evidence-based medicine and research methods; former COVID Pandemic evidence-synthesis consultant advisor to WHO-PAHO Washington, DC (2020) and former senior advisor to COVID Pandemic policy in Health and Human Services (HHS) Washington, DC (A Secretary), US government; worked/appointed in 2008 at WHO as a regional specialist/epidemiologist in Europe's Regional office Denmark, worked for the government of Canada as an epidemiologist for 12 years, appointed as the Canadian in-field epidemiologist (2002-2004) as part of an international CIDA funded, Health Canada executed project on TB/HIV co-infection and MDR-TB control (involving India, Pakistan, Nepal, Sri Lanka, Bangladesh, Bhutan, Maldives, Afghanistan, posted to Kathmandu); employed from 2017 to 2019 at Infectious Diseases Society of America (IDSA) Virginia USA as the evidence synthesis meta-analysis systematic review guideline development trainer; currently a COVID-19 consultant researcher in the US-C19 research group.

8- Share f Share 💙 Tweet in 0 🕫 0

FILED UNDER: HEALTH. NEWS, OPINION

Comments

	th "passport.," an "Immunity Passport" makes more sense than a "Vaccine Passport."	
Reply		
	Publisher says	
	NOVEMBER 5, 2021 AT 458 PM	
м	r. Snyder,	
	, nank you for reading the Herald and taking the time to comment.	
	long a similar line, until Monday, foreign travelers into the U.S. only had to provide	
	roof of a negative test within three days or recovery documentation. Yet, the latter as never been allowed by our own county health officials won't allow that.	
	lso, U.S. Senator Diane Feinstein introduced the U.S. Air Travel Public Safety Act, a bill	
	at would require all passengers on domestic airline flights to either be fully	
	accinated, have recently tested negative for COVID-19 or have fully recovered from	
	OVID-19. According to her office's press release, "the legislation builds on a current DC requirement that all air passengers traveling to the United States from a foreign	
	ountry must provide proof of a negative COVID-19 test result or documentation of	
re	covery from COVID-19."	
	ut our officials said "in our analysis of available research, we determined that the sience remains unsettled around the efficacy or duration of natural immunity	
	lence remains unsettled around the efficacy or duration of natural immunity illowing a COVID-19 infection." – https://contracostaherald.com/contra-costa-	
	ealth-data-show-covid-cases-were-on-decline-before-new-health-orders-issued/	
	ney need to read the 91 studies that have shown natural immunity is better than	
	accine immunity. – https://contracostaherald.com/91-research-studies-affirm- aturally-acquired-immunity-to-covid-19-documented-linked-and-quoted/	
	llen Payton, Publisher	
Re	eply	
Leave a	a Reply	
	a Reply address will not be published. Required fields are marked *	
Your email		
Your email Comment Name *		
Your email Comment Name * Email *	address will not be published. Required fields are marked	
Your email Comment		
Your email Comment Name ' Email ' Website	address will not be published. Required fields are marked '	
Your email Comment Name * Email *	address will not be published. Required fields are marked '	